Retrospective Evaluation of GGPSP's Safety and Clinical Performance for the Treatment of Lower Limbs Deformities.

August 25, 2022 updated by: Orthofix s.r.l.

Retrospective Clinical Study for the Evaluation of the Safety and Clinical Performance of the Medical Device "Guided Growth Plate System Plus" (GGPSP) for the Treatment of Bone Deformities of the Lower Limbs in Skeletally Not Mature Children.

Orthofix is conducting this retrospective Post-market clinical follow up (PMCF) study to assess the safety and clinical performance of the GGPSP device, which is a new version of the Guided Growth Plate System (GGPS) from which it differs for small modifications compared to the original design. The purpose of the study is to collect clinical evidence from the use of the device in a representative number of pediatric patients who have already been treated with the device in the study and with at least one control visit post removal of plaque..

For this purpose, a retrospective PMCF study was considered to be the most appropriate study design to obtain the necessary information.

Study Overview

Detailed Description

GGPSP (also named 8 Plate Plus) has been developed to redirect long bone growth and is used to correct gradually angular deformity in growing children. The device is indicated for the treatment of specific conditions/pathologies between which:

  • deformity of the knee (femur and / or tibia) in varum/valgus or flexural extension;
  • deformity of the ankle in varum/valgus or plantar flexion;
  • femur and/or tibia length discrepancy.

Objectives:

The primary objective of the clinical investigation is to assess the safety of the 8 Plate Plus.

The secondary objective of the clinical investigation is to assess the clinical benefit of the 8 Plate Plus.

The Investigator will include in the study the patients who at the screening visit (Visit 0) will meet all the selection criteria. It is understood that, given the retrospective nature of the study and given that the consent of eligible patients has been collected in advance, the patient should not attend the screening visit or subsequent visits. In addition, during the screening visit (Visit 0) the Investigator will collect demographic data and patient history.

Subsequently, the data of interest relating to the surgery for the application of the plate (Visit 1) and the period of treatment will be collected, or related to the 2 follow up visits (Visits 2 and 3) carried out until or at the removal of the plate/ plates (Visit 4).

The course of treatment will be monitored as per clinical practice and will then be collected data that correspond to the follow-up visit planned on average 4 months after removal of the plate/plates (visit 5).

Study Type

Observational

Enrollment (Actual)

69

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bologna, Italy, 40136
        • Istituto Ortopedico Rizzoli

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 17 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Paediatric patients with open physis (growing children) who have been diagnosed with an angular deformity or discrepancy in length of femur and/or tibia.

Patients must not be over 18 years of age at the time of implantation.

Description

Inclusion Criteria:

  • he/she has been diagnosed with an angular deformity or discrepancy in length of femur and/or tibia
  • at the time of treatment he/she had not yet reached the age of 18;
  • at the time of treatment the growth plates of the treated limbs was not already closed;
  • according to the Investigator's judgment, angular deformity and/or length discrepancy had a regular indication for surgical treatment with tensioning plates
  • deformity was treated with the 8 Plate Plus , according to the manufacturer's instructions
  • the treatment with 8 Plate Plus was completed and the patient had at least one post-removal control of the plate
  • clinical patient data for the evaluation of safety and benefit of the device are still available

Exclusion Criteria:

  • Not treated with 8 Plate Plus to correct upper limb deformities only and not lower limb deformities
  • its clinical data are no longer accessible and /or do not allow the evaluation of the safety and benefit of the device under study
  • had a medical condition which constitutes a contraindication to treatment with 8 Plate Plus in accordance with the manufacturer's instructions for use;
  • at the same time was treated with an unauthorised device which could not be removed without putting the patient's safety at risk.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Pediatric patients treated with GGPSP for the correction of femur and/or tibia deformities
The implant is thought as one of the surgical options to perform epiphysiodesis and hemiepiphysiodesis minimally invasive, that is without recourse to a corrective osteotomy.
Other Names:
  • 8-Plate Plus

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety measurement: percentage of subjects who during the observation period have at least one complication certainly or potentially related to the device in the studio
Time Frame: through study completion, an average of 2 years

Such complications shall be understood as:

  • a serious adverse event expected or not expected
  • a hardware failure (for example, breaking, detaching or folding of the plate or screws).
through study completion, an average of 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Efficacy measurement: the percentage of subjects that during the observation period have achieved the treatment objectives
Time Frame: through study completion, an average of 2 years

The treatment objectives are defined as:

  • for hemiepiphysiodesis, angular deformity of the femur and/or partially tibia; or Fully correct in the direction of the standard alignment (mMPTA and mLDFA between 85° and 89°);
  • for epiphysiodesis, a discrepancy in the length of the femur and/or tibia which is partially or completely correct in relation to the morphologically normal contralateral length of the limb.
through study completion, an average of 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 16, 2021

Primary Completion (Actual)

January 24, 2022

Study Completion (Actual)

January 24, 2022

Study Registration Dates

First Submitted

February 2, 2022

First Submitted That Met QC Criteria

February 15, 2022

First Posted (Actual)

February 16, 2022

Study Record Updates

Last Update Posted (Actual)

August 26, 2022

Last Update Submitted That Met QC Criteria

August 25, 2022

Last Verified

August 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Joint Diseases

Clinical Trials on Guided Growth Plate System Plus

3
Subscribe